Pharmacogenetic Basis for Therapeutic Optimization in Alzheimer’s Disease (original) (raw)
Cacabelos R. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer’s disease. Aging Health 2005; 1: 303–48 ArticleCAS Google Scholar
Cacabelos R, Takeda M. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer’s disease. Drugs Future 2006; 31Suppl. B: 5–146 Google Scholar
Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nature Rev Genet 2003; 4: 937–47 ArticlePubMedCAS Google Scholar
Austin CP. The impact of the completed human genome sequence on the development of novel therapeutics for human disease. Annu Rev Med 2004; 55: 1–13 ArticlePubMedCAS Google Scholar
Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Hum Genet 2006; 7: 223–45 ArticlePubMedCAS Google Scholar
Emilien G, Ponchon M, Caldas C, et al. Impact of genomics on drug discovery and clinical medicine. Q J Med 2000; 93: 391–423 ArticleCAS Google Scholar
Verrils NM. Clinical proteomics: present and future prospects. Clin Biochem Rev 2006; 27: 99–116 Google Scholar
Cacabelos R, Alvarez XA, Lombardi V, et al. Pharmacological treatment of Alzheimer disease: from phychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today 2000; 36: 415–99 PubMedCAS Google Scholar
Giacobini E. Cholinesterases in human brain: the effect of cholinesterase inhibitors on Alzheimer’s disease and related disorders. In: Giacobini E, Pepeu G, editors. The brain cholinergic system in health and disease. Oxon: Informa Healthcare, 2006: 235–64 Google Scholar
Loveman E, Green C, Kirby J, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technl Assess 2006; 10: 1–176 Google Scholar
Cacabelos R, Fernández-Novoa L, Lombardi V, et al. Molecular genetics of Alzheimer’s disease and aging. Meth Find Exper Clin Pharmacol 2005; 27Suppl. A: 1–573 Google Scholar
Cacabelos R. The application of functional genomics to Alzheimer’s disease. Pharmacogenomics 2003; 4: 597–621 ArticlePubMedCAS Google Scholar
Cacabelos R, Alvarez A, Fernández-Novoa L, et al. A pharmacogenomic approach to Alzheimer’s disease. Acta Neurol Scand 2000; 176 Suppl.: 12–9 ArticleCAS Google Scholar
Cacabelos R. Pharmacogenomics in Alzheimer’s disease. Min Rev Med Chem 2002; 2: 59–84 ArticleCAS Google Scholar
Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nature Rev Genet 2004; 5: 645–56 ArticlePubMedCAS Google Scholar
Cacabelos R. Pharmacogenomics and therapeutic prospects in Alzheimer’s disease. Exp Opin Pharmacother 2005; 6: 1967–87 ArticleCAS Google Scholar
Meyer UA. Pharmacogenetics: five decades of therapeutic lessons from genetic diversity. Nature Rev Genet 2004; 5: 669–76 ArticlePubMedCAS Google Scholar
Selkoe DJ, Podlisny MB. Deciphering the genetic basis of Alzheimer’s disease. Annu Rev Genomics Hum Genet 2002; 3: 67–99 ArticlePubMedCAS Google Scholar
Cacabelos R, Fernandez-Novoa L, Corzo L, et al. Genomics and phenotypic profiles in dementia: Implications for pharmacological treatment. Meth Find Exper Clin Pharmacol 2004; 26: 421–44 CAS Google Scholar
Cacabelos R, Kubota Y, Isaza C, et al. Functional genomics and pharmacogenetics in Alzheimer’s disease. In: Hanin I, Cacabelos R, Fisher A, editors. Recent Progress in Alzheimer’s and Parkinson’s Disease. London: Taylor & Francis, 2005: 89–102 Google Scholar
MITOMAP: a human mitochondrial genome database [online]. Available from URL: http://www.mitomap.org/ [Accessed 2007 Nov 15]
Y-H Suh, Checler F. Amyloid precursor protein, presenilins, and α-synuclein: molecular pahogenesis and pharmacological applications in Alzheimer’s disease. Phamacol Rev 2002; 54: 469–525 Google Scholar
Hunter DJ. Gene-environment interactions in human diseases. Nature Rev Genet 2005; 6: 287–98 ArticlePubMedCAS Google Scholar
Teter B, Finch CE. Caliban’s heritance and the genetics of neuronal aging. Trends Neurosci 2004; 27: 627–32 ArticlePubMedCAS Google Scholar
Levenson JM, Sweatt JD. Epigenetic mechanisms in memory formation. Nature Rev Neurosci 2005; 6: 108–18 ArticleCAS Google Scholar
The National Institute of Mental Health Genetics Initiative, Blacker D, Albert MS, Bassett SS, et al. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer’s disease. Arch Neurol 1994; 51: 1198–204 Article Google Scholar
WHO. International statistical classification of diseases and related health problems. 10th Revision Version for 2007 [online]. Available from URL: http://www.who.int/classifications/apps/icd/icdlOonline/ [Accessed 2007 Nov 23]
International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004; 431: 931–45 ArticleCAS Google Scholar
Cacabelos R, Fernández-Novoa L, Pichel V, et al. Pharmacogenomic studies with a combination therapy in Alzheimer’s disease. In: Takeda M, Tanaka T, Cacabelos R, editors. Molecular neurobiology of alzheimer disease and related disorders. Basel: Karger, 2004: 94–107 Chapter Google Scholar
Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538–49 ArticlePubMedCAS Google Scholar
Arranz MJ, Collier D, Kerwin RW. Pharmacogenetics for the individualization of psychiatric treatment. Am J Pharmacogenomics 2001; 1: 3–10 ArticlePubMedCAS Google Scholar
Poirier J, Delisle M-C, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995; 92: 12260–4 ArticlePubMedCAS Google Scholar
Poirier J. Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer’s disease. J Psychiat Neurosci 1999; 24: 147–53 CAS Google Scholar
Almkvist O, Jelic V, Amberla K, et al. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement Geriatr Cogn Disord 2001; 12: 22–32 ArticlePubMedCAS Google Scholar
Sjögren M, Hesse C, Basun H, et al. Tacrine and rate of progression in Alzheimer’s disease: relation to ApoE allele genotype. J Neural Transm 2001; 108: 451–8 ArticlePubMed Google Scholar
Borroni B, Colciaghi F, Pastorino L, et al. ApoE genotype influences the biological effects of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model. Eur Neuropsychopharmacol 2002; 12: 195–200 ArticlePubMedCAS Google Scholar
Aerssens J, Raeymaekers P, Lilienfeld S, et al. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer’s disease. Dement Geriatr Cogn Disord 2001; 2: 69–77 Article Google Scholar
Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261–8 ArticlePubMedCAS Google Scholar
Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics 2006; 6: 246–54 CAS Google Scholar
MacGowan SH, Wilcock GK, Scott M. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer’s disease. Int J Geriatr Psychiatry 1998; 13: 625–30 ArticlePubMedCAS Google Scholar
Rigaud AS, Traykov L, Caputo L, et al. The apolipoprotein E epsilon 4 allele and the response to tacrine therapy in Alzheimer’s disease. Eur J Neurol 2000; 7: 255–8 ArticlePubMedCAS Google Scholar
Rigaud AS, Traykov L, Latour F, et al. Presence of absence of least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer’s disease. Pharmacogenetics 2002; 12: 415–20 ArticlePubMedCAS Google Scholar
Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379–88 ArticlePubMedCAS Google Scholar
Bizzarro A, Marra C, Acciarri A, et al. Apolipoprotein E epsilon-4 allele differentiates the clinical response to donepezil in Alzheimer’s disease. Dement Geriatr Cogn Disord 2005; 20: 254–61 ArticlePubMedCAS Google Scholar
Alvarez XA, Mouzo R, Pichel V, et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients: effects on cognitive performance, brain bioelectrical activity, and cerebral perfusion. Meth Find Exp Clin Pharmacol 1999; 21: 633–44 ArticleCAS Google Scholar
Alvarez XA, Pichel V, Pérez PA, et al. Double-blind, randomized, placebocontrolled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics. Meth Find Exp Clin Pharmacol 2000; 22: 585–94 ArticleCAS Google Scholar
Saunders AM, Trowers MK, Shimkets RA, et al. The role of apolipoprotein E in Alzheimer’s disease: pharmacogenomic target selection. Biochem Biophys Acta 2000; 1502: 85–94 ArticlePubMedCAS Google Scholar
Cacabelos R. Molecular pathology and pharmacogenomics in Alzheimer’s disease: polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression. Meth Find Exper Clin Pharmacol 2007; 29Suppl. B: 1–91 CAS Google Scholar
Cacabelos R, Rodriguez B, Carrera C, et al. Behavioral changes associated with different apolipoprotein E genotypes in dementia. Alzheimer′s Dis Assoc Dis 1997; 11Suppl. 4: S27–37 Google Scholar
Bellivier F, Laplanche JL, Schurhoff F, et al. Apolipoprotein E gene polymorphism in early and late onset bipolar patients. Neurosci Lett 1997; 233: 45–8 ArticlePubMedCAS Google Scholar
van der Flier Wm, Staekenborg S, Pijnenburg YA, et al. Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease. Dement Geriatr Cogn Disord 2006; 23: 42–6 ArticlePubMedCAS Google Scholar
Flicker L, Martins RN, Thomas J, et al. Homocysteine, Alzheimer genes and proteins, and measures of cognition and depression in older men. J Alzheimer Dis 2004; 6: 329–36 CAS Google Scholar
Muller-Thomsen T, Artl S, Ganzer S, et al. Depression in Alzheimer’s disease might be associated with apolipoprotein E epsilon 4 allele frequency in women but not in men. Dement Geriatr Cogn Disord 2002; 14: 59–63 ArticlePubMed Google Scholar
Hollingworth P, Hamshire ML, Moskvina V, et al. Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer’s disease. J Am Geriatr Soc 2006; 54: 1348–54 ArticlePubMed Google Scholar
Craig D, Hart DJ, Mcllroy SP, et al. Association analysis of apolipoprotein E genotype and risk of depressive symptoms in Alzheimer’s disease. Dement Geriatr Cogn Disord 2005; 19: 154–7 ArticlePubMedCAS Google Scholar
Gabryelewicz T, Religa D, Styczynska M, et al. Behavioural pathology in Alzheimer’s disease with special reference to apolipoprotein E genotype. Dement Geriatr Cogn Disord 2002; 14: 208–12 ArticlePubMedCAS Google Scholar
Steffens DC, Norton MC, Hart AD, et al. Apolipoprotein E genotype and major depression in a community of older adults. The Cache County Study. Psychol Med 2003; 33: 541–7 ArticlePubMedCAS Google Scholar
Steinberg M, Corcoran C, Tschanz JT, et al. Risk factors for neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2006; 21: 824–30 ArticlePubMedCAS Google Scholar
Nebes RD, Vora IJ, Meltzer CC, et al. Relationship of deep white matter hyperintensities and apolipoprotein E genotype to depressive symptoms in older adults without clinical depression. Am J Psychiatry 2001; 158: 878–84 PubMedCAS Google Scholar
Naismith S, Hickie I, Ward PB, et al. Caudate nucleus volumes and genetic determinants of homocysteine metabolism in the prediction of psychomotor speed in older persons with depression. Am J Psychiatry 2002; 159: 2096–8 ArticlePubMed Google Scholar
O’Brien JT, Lloyd A, McKeith I, et al. A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects. Am J Psychiatry 2004; 161: 2081–90 ArticlePubMed Google Scholar
Hickie I, Naismith S, Ward PB, et al. Reduced hippocapal volumes and memory loss in patients with early- and late-onset depression. Br J Psychiatry 2005; 186: 197–202 ArticlePubMed Google Scholar
Kim JM, Stewart R, Shin IS, et al. Vascular/risk and late-life depression in a Korean community population. Br J Psychiatry 2004; 185: 102–7 ArticlePubMed Google Scholar
Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293: 596–608 ArticlePubMedCAS Google Scholar
Tribut O, Lessard Y, Reymann JM, et al. Pharmacogenomics. Med Sci Monit 2002; 8: 152–63 Google Scholar
Saito S, Ishida A, Sekine A, et al. Catalog of 680 variants among eight cytochrome P450 (CYP) genes: nine esterase genes, and two other genes in the Japanese population. J Hum Genet 2003; 48: 249–70 ArticlePubMedCAS Google Scholar
Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nature Rev Drug Discov 2006; 5: 956–70 ArticleCAS Google Scholar
Hedlund E, Gustafsson JA, Warner M. Cytochrome P450 in the brain: a review. Curr Drug Metabol 2001; 2: 245–63 ArticleCAS Google Scholar
Isaza CA, Henao J, López AM, et al. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Meth Find Exp Clin Pharmacol 2000; 22: 695–705 ArticleCAS Google Scholar
The International Centre for Genetic Engineering and Biotechnology [online]. Available from URL: http://www.icgeb.org/ [Acessed 2007 Nov 15]
Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee [online]. Available from URL: http://www.imm.ki.se/CYPalleles/cyp2d6.htm [Acessed 2007 Nov 15]
Wooding SP, Watkins WS, Bamshad MJ, et al. DNA sequence variations in a 3.7-kb noncoding sequence 5-prime of the CYP1A2 gene: implications for human population history and natural selection. Am J Hum Genet 2002; 71: 528–42 ArticlePubMedCAS Google Scholar
Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 2003; 35: 99–106 ArticlePubMedCAS Google Scholar
Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, et al. Polymorphisms of drugmetabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003; 59: 303–12 ArticlePubMedCAS Google Scholar
Xie HG, Prasad HG, Kim RB, et al. CYP2C9 allelic variants: ethnic ditribution and functional significance. Adv Drug Deliv Rev 2002; 54: 1257–70 ArticlePubMedCAS Google Scholar
Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharm Toxicol 2001; 41: 815–50 ArticleCAS Google Scholar
Bentue-Ferrer D, Tribut O, Polard E, et al. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 2003; 17: 947–63 ArticlePubMedCAS Google Scholar
Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284–95 PubMedCAS Google Scholar
Griese E-U, Zanger UM, Brudermanns U, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8: 15–26 ArticlePubMedCAS Google Scholar
Bernai ML, Sinues B, Johansson I, et al. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics 1999; 9: 657–60 Article Google Scholar
Cacabelos R. Donepezil in Alzheimer’s disease: from conventional trials to pharmacogenetics. Neuropsychiat Dis Treat 2007; 3: 1–31 Article Google Scholar
Bernard S, Neville KA, Nguyen AT, et al. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 2006; 11: 126–35 ArticlePubMedCAS Google Scholar
Raimundo S, Fischer J, Eichelbaum M, et al. Elucidation of the genetic basis of the common intermediate metabolizer phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000; 10: 577–81 ArticlePubMedCAS Google Scholar
Rasmussen JO, Christensen M, Svendsen JM, et al. CYP2D6 gene test in psycgiatric patients and healthy volunteers. Scand J Clin Lab Invest 2006; 66: 129–36 ArticlePubMedCAS Google Scholar
Chen X, Xia Y, Alford M, et al. The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer’s disease. Ann Neurol 1995; 38: 653–8 ArticlePubMedCAS Google Scholar
Yamada H, Dahl ML, Viitanen M, et al. No association between familial Alzheimer disease and cytochrome P450 polymorphisms. Alzheimer Dis Assoc Disord 1998; 12: 204–7 ArticlePubMedCAS Google Scholar
Cervilla JA, Russ C, Holmes C, et al. CYP2D6 polymorphisms in Alzheimer’s disease, with and without extrapyramidal signs, showing no apolipoprotein E epsilon 4 effect modification. Biol Psychiatry 1999; 45: 426–9 ArticlePubMedCAS Google Scholar
Atkinson A, Singleton AB, Steward A, et al. CYP2D6 is associated with Parkinson’s disease but not with dementia with Lewy bodies or Alzheimer’s disease. Pharmacogenetics 1999; 9: 31–5 ArticlePubMedCAS Google Scholar
Nicholl DJ, Bennett P, Hiller L, et al. A study of five candidate genes in Parkinson’s disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. Neurology 1999; 53: 1415–21 ArticlePubMedCAS Google Scholar
Woo SI, Kim JW, Seo HG, et al. CYP2D6*4 polymorphism is not associated with Parkinson’s disease and has no protective role against Alzheimer’s disease in the Korean population. Psychiatry Clin Neurosci 2001; 55: 373–7 ArticlePubMedCAS Google Scholar
Furuno T, Kawanishi C, Iseki E, et al. No evidence of an association between CYP2D6 polymorphisms among Japanese and dementia with Lewy bodies. Psychiatry Clin Neurosci 2001; 55: 89–92 ArticlePubMedCAS Google Scholar
Scordo MG, Dahl ML, Spina E, et al. No association between CYP2D6 polymorphisms and Alzheimer’s disease in an Italian population. Pharmacol Res 2006; 53: 162–5 ArticlePubMedCAS Google Scholar
Cacabelos R. Pleiotropic effects of APOE in dementia: Influence on functional genomics and pharmacogenetics. In: Fisher A, Hanin I, Stocchi F, et al., editors. Advances in Alzheimer’s and Parkinson’s disease: insights, progress, and perspectives. Secaucus (NJ): Springer. In press
Varsaldi F, Miglio G, Scordo MG, et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer’s disease patients. Eur J Clin Pharmacol 2006; 62: 721–6 ArticlePubMedCAS Google Scholar
Egger SS, Bachmann A, Hubmann N, et al. Prevalence of potentially inappropriate medication use in elderly patients: comparison between general medicine and geriatric wards. Drugs Aging 2006; 23: 823–37 ArticlePubMed Google Scholar
Schuetz EG, Relling MV, Kishi S, et al. PharGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5. Pharmacol Rev 2004; 56: 159 ArticlePubMedCAS Google Scholar
Harold D, Macgregor S, Patterson CE, et al. A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer’s disease. Pharmacogenet Genomics 2006; 16: 75–7 ArticlePubMedCAS Google Scholar
Sayed-Tabatabaei FA, Oostra BA, Isaacs A, et al. ACE polymorphisms. Circ Res 2006; 98: 1123–33 ArticlePubMedCAS Google Scholar
Hu J, Igarashi A, Kamata M, et al. Angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide (Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 2001; 276: 47863–8 PubMedCAS Google Scholar
Oba R, Igarashi A, Kamata M, et al. The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. Eur J Neurosci 2005; 21: 733–40 ArticlePubMed Google Scholar
Eckman EA, Adams SK, Troendle FJ, et al. Regulation of steady-state betaamyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 2006; 281: 30471–8 ArticlePubMedCAS Google Scholar
Hemming ML, Selkoe DJ. Amyloid β-protein is degraded by cellular angiotensinconverting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005; 280: 37644–50 ArticlePubMedCAS Google Scholar
Hogan DB, Goldlist B, Naglie G, et al. Comparison studies of cholinesterase inhibitors for Alzheimer’s disease. Lancet Neurol 2004; 3: 622–8 ArticlePubMedCAS Google Scholar
Philips KA, Van Bebber SL. Measuring the value of pharmacogenomics. Nature Rev Drug Discovery 2005; 4: 500–9 ArticleCAS Google Scholar